Skip to content

ImmunityBio, Inc. IBRX Goodwill and Intangible Assets, Net

Goodwill and Intangible Assets, Net at other companies

United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetIncludingGoodwill.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s goodwill and intangible assets, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s goodwill and intangible assets, net?
ImmunityBio, Inc. (IBRX) reported goodwill and intangible assets, net of $12.89M in Q1 2026.
How has ImmunityBio, Inc.'s goodwill and intangible assets, net changed year-over-year?
ImmunityBio, Inc.'s goodwill and intangible assets, net decreased by 16.6% year-over-year, from $15.44M to $12.89M.
What is the long-term trend for ImmunityBio, Inc.'s goodwill and intangible assets, net?
Over 2 years (2023 to 2025), ImmunityBio, Inc.'s goodwill and intangible assets, net has grown at a -9.7% compound annual growth rate (CAGR), from $17.09M to $13.95M.